$Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study$

Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

Abstract Background Glucocorticoids are associated with increased fracture risk and are the mainstay of treatment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, fracture risk in these conditions has not been previously quantified. The aim of this study was to quantify the r...

Bibliografske podrobnosti
Main Authors:	Zoe Paskins, Rebecca Whittle, Alyshah Abdul Sultan, Sara Muller, Milica Blagojevic-Bucknall, Toby Helliwell, Samantha Hider, Edward Roddy, Christian Mallen
Format:	Article
Jezik:	English
Izdano:	BMC 2018-01-01
Serija:	BMC Medicine
Teme:	Fracture Osteoporosis Glucocorticoids Polymyalgia Giant cell arteritis
Online dostop:	http://link.springer.com/article/10.1186/s12916-017-0987-1

Podobne knjige/članki

Possible giant cell arteritis symptoms are common in newly diagnosed patients with Polymyalgia Rheumatica: results from an incident primary care PMR cohort
od: William Masson, et al.
Izdano: (2017-12-01)

Comorbidities in polymyalgia rheumatica: a systematic review
od: Richard Partington, et al.
Izdano: (2018-11-01)

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
od: Yannick van Sleen, et al.
Izdano: (2019-08-01)

A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis
od: Hoon E, et al.
Izdano: (2019-08-01)

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
od: Alexey D. Meshkov, et al.
Izdano: (2024-09-01)

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
od: Rosanne D. Reitsema, et al.
Izdano: (2023-08-01)

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
od: Andriko Palmowski, et al.
Izdano: (2022-02-01)

The evolution of diagnosis of polymyalgia rheumatica
od: A. M. Satybaldyev
Izdano: (2019-12-01)

Central retinal vein oclussion as presentation of giant cell arteritis and polymyalgia rheumatica. Case report.
od: Jersson Camilo Sanchez-Gamez, et al.
Izdano: (2022-05-01)

Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica
od: Ciro Manzo
Izdano: (2016-11-01)

Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases
od: D. Camellino, et al.
Izdano: (2024-10-01)

Normal ESR, CRP and Platelet Count in Giant Cell Arteritis and Polymyalgia Rheumatica: A Diagnostic Conundrum
od: Abdullahi Elsheikh Mahgoub, et al.
Izdano: (2022-02-01)

Presence of subclinical giant cell arteritis in patients with morning stiffness of duration less than 45 minutes at the time of diagnosis of polymyalgia rheumatica
od: Ciro Manzo, et al.
Izdano: (2024-01-01)

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
od: Evgeny L. Nasonov, et al.
Izdano: (2024-09-01)

Vascular-adhesion protein 1 in giant cell arteritis and polymyalgia rheumatica
od: Simon M. Petzinna, et al.
Izdano: (2024-08-01)

Polymyalgia Rheumatica (PMR) and Lung Involvement: The Forgotten Association
od: Hoda Mohamed Bakri Hammoda, et al.
Izdano: (2020-03-01)

Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
od: Pierre-André Jarrot, et al.
Izdano: (2024-12-01)

Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
od: Guillermo Carvajal Alegria, et al.
Izdano: (2023-06-01)

Antimitochondrial Antibodies and Primary Biliary Cholangitis in Patients with Polymyalgia Rheumatica/Giant Cell Arteritis
od: Ciro Manzo, et al.
Izdano: (2021-04-01)

Non-Invasive Metabolic and Structural Retinal Markers in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Cross-Sectional Study
od: Simon J. Lowater, et al.
Izdano: (2022-09-01)

Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case–control study
od: Brault C, et al.
Izdano: (2018-10-01)

POLYMYALGIA RHEUMATICA
od: A. M. Satybaldyev, et al.
Izdano: (2018-05-01)

International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results
od: T. V. Beketova, et al.
Izdano: (2016-10-01)

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica
od: Kornelis S. M. van der Geest, et al.
Izdano: (2022-06-01)

The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome
od: S. Muller, et al.
Izdano: (2018-03-01)

Polymyalgia rheumatica in the 2018–2020 guidelines. Part II: diagnosis of vasculitis
od: О.H. Puzanova, et al.
Izdano: (2021-04-01)

Giant cell arteritis with cervical radiculopathy mimicking polymyalgia rheumatica and elderly-onset rheumatoid arthritis: a case report
od: Akihiko Nakabayashi, et al.
Izdano: (2021-10-01)

Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT
od: Tanja Fromberg Gorlen, et al.
Izdano: (2024-02-01)

Polymyalgia rheumatica in the 2018–2020 clinical guidelines. Part I. At-risk groups, adjuvant therapy
od: О.G. Puzanovа
Izdano: (2020-11-01)

A Case of Clinical Uncertainty Solved: Giant Cell Arteritis with Polymyalgia Rheumatica Swiftly Diagnosed with Long Axial Field of View PET
od: Pieter H. Nienhuis, et al.
Izdano: (2022-11-01)

Polymyalgia rheumatica presenting as sternoclavicular arthritis: a case report
od: Liyana Arachchige Dona Thulini Madubashini, et al.
Izdano: (2022-12-01)

Use of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients affected by polymyalgia rheumatica and persistent increase of acute phase reactants
od: Michele Colaci, et al.
Izdano: (2022-11-01)

The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica
od: Berit D. Nielsen, et al.
Izdano: (2024-07-01)

Headache attributed to giant cell arteritis complicated with rheumatic polymyalgia diagnosed with F18-fluorodeoxyglucose positron emission tomography and computed tomography: a case report
od: Dong Wang, et al.
Izdano: (2023-09-01)

The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity
od: Montecucco Carlomaurizio, et al.
Izdano: (2011-05-01)

Giant cell arteritis: is the clinical spectrum of the disease changing?
od: Miguel Á. González-Gay, et al.
Izdano: (2019-07-01)

Onset of multiple myeloma with rheumatic polymyalgia
od: E. R. Israelyan, et al.
Izdano: (2019-12-01)

The epidemiology of polymyalgia rheumatica in primary care: a research protocol
od: Muller Sara, et al.
Izdano: (2012-06-01)

Large-vessel giant cell arteritis: A rare cause of stroke
od: Himanshu Pathak, et al.
Izdano: (2017-01-01)

Biologic Therapies for Giant Cell Arteritis
od: Harrington R, et al.
Izdano: (2021-01-01)